RxDoctor Payments Data

Kee No, MD

Internal Medicine · Las Vegas, NVNPI 1811902596

Payments from drug & device makers

$2,203in general payments, 2019–2025

Across 90 payments — averaging $24.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$590
  • Abbott$256
  • Lilly USA, LLC$210
  • Novo Nordisk$205
  • Pfizer$187
  • Mylan Specialty L.p.$143
  • plus $611 from 13 others

What the payments were for

  • Food & beverage$2,06394%
  • Education$1406%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,203 in reported general payments places this provider in the 80th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$40,563
Medicare patients
126
Services billed
416

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide88$91,667
JardianceEmpagliflozin64$65,790
EliquisApixaban28$34,885
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$26,696
XareltoRivaroxaban19$19,484
LinzessLinaclotide15$13,171
Atorvastatin Calcium197$3,945
Humulin 70-30Insulin Nph Hum/Reg Insulin Hm12$1,814
Duloxetine Hcl42$1,684
Gabapentin91$1,646
Metoprolol Succinate56$1,533
Losartan Potassium104$1,391
Albuterol Sulfate HfaAlbuterol Sulfate46$1,374
Levothyroxine Sodium91$1,284
Rosuvastatin Calcium60$1,271

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$205$91,66788 claims
Boehringer IngelheimJardiance$44$65,79064 claims
PfizerEliquis$187$34,88528 claims
GSKTrelegy Ellipta$63$26,69631 claims
Johnson & JohnsonXarelto$102$19,48419 claims
AbbVieLinzess$80$13,17115 claims
Lilly USA, LLCHumulin 70-30$210$1,81412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →